- In patients with systemic lupus erythematosus (SLE) with associated Sjogren's syndrome (aSjS), the anti-CD22 monoclonoal IgG antibody epratuzumab showed safety and improvements in SLE disease activity, including decreases in B cells compared with patients with SLE without aSjS.
Why this matters
- Epratuzumab warrants further clinical study in this subpopulation of patients with SLE.
- This was a post hoc analysis of the EMBODY clinical trials in which 1584 patients with SLE were randomly assigned to epratuzumab or placebo.
- 113 patients with SLE with aSjS were compared with 1375 patients with SLE without aSjS.
- Funding: UCB Pharma.
- A higher percentage of epratuzumab patients with aSjS achieved a BICLA (British Isles Lupus Assessment Group [BILAG] Combined Lupus Assessment) response and a lowering from baseline of BILAG total score (P<.05>
- Patients with vs without aSjS had faster B-cell reduction, as measured by lower mean concentration producing 50% of the maximum B-cell count depletion (9.47 vs 87.1 μg/mL).
- There was no difference between epratuzumab and placebo in the frequency of adverse events.
- Post hoc analysis.